A syringe type ejection device capable of reducing an amount of residual liquid is provided. A syringe type ejection device includes: a barrel; a nozzle disposed to face the barrel; and a core inserted in the nozzle, the barrel having a large-diameter portion provided with a discharge space for discharging liquid, the nozzle being provided with a holding space for holding the core, the holding space being in communication with the discharge space, and the core being inserted in the discharge space.

A beneficial agent dispensing device comprises a dispenser body comprising a pressure chamber and at least one dispensing port. A flexible primary container stores the beneficial agent contained within the body. The arrangement is such that pressure in the pressure chamber depress the flexible primary container to expel the beneficial agent through the dispensing port. The beneficial agent dispenser can be configured to deliver the beneficial agent intranasally.

A beneficial agent dispensing device comprises a dispenser body comprising a pressure chamber and at least one dispensing port. A flexible primary container stores the beneficial agent contained within the body. The arrangement is such that pressure in the pressure chamber depress the flexible primary container to expel the beneficial agent through the dispensing port. The beneficial agent dispenser can be configured to deliver the beneficial agent intranasally.

A fluid jet ejection device, a method of making a fluid jet ejection head, and a method of improving the plume characteristics of fluid ejected from the fluid jet ejection head. The pharmaceutical drug delivery device includes a cartridge body; and a fluid jet ejection cartridge disposed in the cartridge body. The fluid jet ejection cartridge contains a fluid and an ejection head attached to the fluid jet ejection cartridge. The ejection head contains a plurality of fluid ejectors thereon and a nozzle plate having a plurality of fluid ejection nozzles therein associated with the plurality of fluid ejectors. At least one of the plurality of fluid ejection nozzles has an orthogonal axial flow path relative to a plane defined by the nozzle plate and at least one of the plurality of fluid ejection nozzles has an angled axial flow path relative to a plane define by the nozzle plate.

A system for treating or providing prophylaxes against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

A system for treating or providing prophylaxes against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.

A gas therapy system (1) has a flow line (3, 2), a coupler (6) to a gas source, and an aerosol generator (4) for aerosol delivery, and a patient interface such as a nasal interface (2). A controller (10) is configured to modulate gas flow and aerosol delivery in real time. The controller changes gas flow rate and dynamically reduces aerosol delivery during upper gas flow rates such as 60 LPM, and activates aerosol delivery during lower gas flow rates of for example 10 LPM. The control may also include sensors to detect breathing, so that there is a bias towards increased aerosol delivery during inhalation in addition to during lower level gas flow.

Provided are methods and devices useful for treating a respiratory disease or disorder involving the central or upper airways. The methods and devices deliver to central or upper airways of a subject a vapor or aerosol comprising an effective amount of an active ingredient selected from the group consisting of menthol, menthone, neomenthol, isomenthol, and menthofuran. The methods are useful for treating conditions including cough, asthma, bronchitis, and allergic rhinitis.

Provided are methods and devices useful for treating a respiratory disease or disorder involving the central or upper airways. The methods and devices deliver to central or upper airways of a subject a vapor or aerosol comprising an effective amount of an active ingredient selected from the group consisting of menthol, menthone, neomenthol, isomenthol, and menthofuran. The methods are useful for treating conditions including cough, asthma, bronchitis, and allergic rhinitis.

A container for holding, dispensing and/or storing a preferably liquid medicament preparation is proposed, which comprises an inner space for the medicament preparation and an at least partially multi-layered wall structure defining the inner space, the wall structure comprising a first layer with a first through-opening of less than 40 μm. Alternatively or additionally, the wall structure comprises a second and third layer, a second through-opening being provided in the second layer and the third layer covering or closing off the wall structure.